This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): AM 80, retinobenzoic acid, Amnoid, Tamibaro, AMNOLAKE (Japan)
Tamibarotene is a synthetic retinoic acid receptor alpha (RARa) agonist.
RARs are normally activated by all-trans retinoic acid (ATRA) and 9-cis retinoic acid which results in downstream transcription of target genes. In published studies, ATRA enhanced the efficacy of paclitaxel/cisplatin-based chemotherapy in NSCLC (JCO 2010: 3463-3471).
Deal Structure: Tamibarotene was developed with Nippon Shinyaku as a potential treatment for acute promyelocytic leukaemia (APL). Tamibarotene was being developed by Shionogi in Japan but the company subsequently discontinued its involvement. Various nonindustrial sources, such as the University of Tokyo, Japan, have also played a role in the development of tamibarotene. Nippon Shinyaku licensed the rights to tamibarotene from Toko Pharmaceutical Industries for the treatment of acute promyelocytic leukaemia.
Innovive and TMRC
In December 2006, INNOVIVE Pharmaceuticals acquired exclusive North American rights to develop and commercialize Tamibarotene. Under the terms of the agreement, INNOVIVE acquired the exclusive North American license from TMRC, Co., Ltd. to develop and commercialize Tamibarotene for treatment of APL, with an option to include within the license the use of Tamibarotene in other fields in oncology including multiple myeloma, myelodysplastic syndrome and solid...See full deal structure in Biomedtracker
Partners: TMRC Co., Ltd. Nippon Shinyaku Co., Ltd. CytRx Corporation
Additional information available to subscribers only: